A multidisciplinary team and a patient advocate discuss use of PARP inhibitors in mCRPC
touchONCOLOGY presents the top new clinical trial findings that are generating a buzz among prostate cancer experts. Here’s the latest from one of the leading global conferences in GU oncology: the 2025 ASCO Genitourinary Cancers Symposium (February 26–28, 2025, San Francisco, CA, ...
It is with great pleasure that we present the latest edition of touchREVIEWS in Oncology & Haematology. This issue highlights the remarkable progress and innovation shaping the fields of oncology and haematology, featuring articles that delve into both emerging therapies ...
Metastatic castration-resistant prostate cancer (mCRPC) represents the most formidable stage of prostate cancer (PCa) and is responsible for the majority of PCa-related mortalities. This advanced form of the disease typically evolves from less aggressive stages.1 PCa is broadly categorized into ...
The uniquely designed Prostate Biomarker (ProBio) study (NCT03903835) used outcome-adaptive randomization to compare biomarker-driven treatment selection against physician’s choice, and to compare androgen receptor inhibitors (ARPIs) against standard-of-care (SOC) and taxanes in castrate-resistant prostate cancer (mCRPC). To learn more ...
In the PROpel trial, abiraterone and olaparib significantly prolonged radiographic progression free survival in patients with metastatic castration-resistant prostate cancer. Prof. Fred Saad (University of Montreal Hospital Centre, Université de Montréal, Quebec, Canada) joins touchONCOLOGY to discuss the biomarker ...
Androgen deprivation therapy (ADT) has been the cornerstone of the treatment of metastatic prostate carcinoma for over 70 years, ever since Huggins and Hodges first treated men with prostate carcinoma with orchidectomy or oestrogen injection in 1941.1Â However, the treatment landscape of ...
ASCO 2022 showcased many important studies in prostate cancer. Prof. Axel Merseburger (Department of Urology, University of Lubeck, Germany), touchONCOLOGY's Editor-in-Chief, joins us to share his highlights. In this interview he discusses: the phase 3 trial of SHR3680 versus bicalutamide in combination ...
Dr Kim Chi (The University of British Columbia, Vancouver, BC, Canada) summarises the first results of the phase 3 MAGNITUDE (NCT03748641) study of niraparib with abiraterone acetate and prednisone as first-line therapy in patients with metastatic castration-resistant prostate cancer with and ...
Welcome to the winter edition of touchREVIEWS in Oncology & Haematology. Despite the continued impact of the COVID-19 pandemic on cancer care, 2021 has seen important advances in many areas of oncology, which is reflected in our diverse range of articles. ...
Prostate cancer is one of the leading causes of cancer death worldwide.1Â However, the emergence of novel hormonal therapies and the increasing availability of sensitive next-generation imaging techniques, such as gallium-88 prostate-specific membrane antigen (PSMA)-targeted positron emission tomography (PET), ...
The American Cancer Society estimates that approximately 248,530 new cases of prostate cancer will be diagnosed in the United States in 2021.1Â For the nearly 90% of patients diagnosed with locoregional prostate cancer, the goal of treatment by surgical intervention or radiation is ...
Cervical cancer (CC) is the fourth most common female malignancy, with 640,127 new cases and 341,831 deaths in 2020 worldwide. Despite the introduction of screening programmes and vaccination campaigns, CC still represents one of the leading causes of cancer-related death in women.1 The ...
touchONCOLOGY joins Professor Neeraj Agarwal (Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA) at ESMO 2021 to discuss the much-anticipated results of the COSMIC-021 study of cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer. ...
Prostate cancer is the second most common cause of cancer mortality in men, with most deaths occurring as a result of metastatic disease that has become resistant to androgen deprivation therapy (ADT).1Â Most recently, immunotherapy, in the form of immune ...
The American Society of Clinical Oncology (ASCO) 2020 meeting was held virtually this year due to the COVID-19 pandemic. Despite this, there were hundreds of abstracts, posters and presentations. In an interview, Axel S. Merseburger, chairman of the Department of Urology ...
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Register for free to hear about the latest expert-led education, peer-reviewed articles, conference highlights, and innovative CME activities.
Or use a Social Account.
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.